toxicology-conference-2017-scientifictracks

Page 20

Notes:

allied

academies

J Clin Exp Tox 2017 Volume 1 | Issue 2

Toxicology and Pharmacology

November 01-02, 2017 | Toronto, Canada

International Conference on

n recent years, human stem cell-derived cardiomyocytes

(hiPSC-CMs) have proven to represent a relevant human

in-

vitro

system for modeling and interrogating complex biological

processes, phenotypic profiles and disease models. Chip-based

approaches allow parallel patch clamp recordings without

compromising data quality or technical sophistication. We

present high-throughput ion channel recordings in hiPSC-

CMs using Nanion’s automated patch clamping systems.

The CardioExcyte 96 is a hybrid screening instrument that

combines impedance with MEA-like extracellular field potential

(EFP) recordings. In the light of the new Comprehensive

Proarrhythmia Assay (CiPA), a FDA directed initiative to improve

guidelinesandstandardizeassaysandprotocols,theuseofhiPSC-

CMs may become critical in determining the proarrhythmic

risk of potential drug candidates. In accordance with the CiPA

guidelines, we present pharmacological investigations of short-

and long-term effects of compounds from each risk category,

in hiPSC-CMs. This approach strengthens the importance of

testing compounds in assays complementary to patch clamp

electrophysiology, to provide a more complete safety profile.

Speaker Biography

Corina T Bot obtained her PhD in Applied Physics from New Jersey Institute of

Technology in 2010. Next, she worked for two years as a Post-doctoral Associate in

Cardiology, at Cornell University, Weill Cornell Medical College. In her current position

as a Senior Scientist at Nanion Technologies, she provides technical and scientific

support for cell-based electrophysiology and toxicology assays, and automated patch

clamp screening. Together with her colleagues at Nanion, she is participating in the

FDA-directed Comprehensive

in vitro

Proarrhythmia Assay (CiPA) initiative, which

aims to replace the preclinical hERG current assay required under the ICH S7B safety

pharmacology guidelines and clinical TQT study.

Corina T Bot

Nanion Technologies, Germany

Short and long-term cytotoxicity investigations in stem cells for primary and

secondary assays with an all- inclusive approach